Objective-To examine the effects of aspirin on the potential for oxidative modification of low density lipoprotein (LDL).
Hypercholesterolaemia is well established as an important cause of coronary artery disease and the benefit of reducing blood cholesterol in both primary and secondary prevention of coronary artery disease is well established.' 2 Hypercholesterolaemia per se is not the only causative factor, however, as at any blood cholesterol concentration there is considerable variation in the clinical expression of the disease.3
One basis for such variation rests with the complex nature of the biological response of arterial wall cells to the various postsecretory modifications in the structure of lipoproteins and in particular of low density lipoprotein (LDL). Over the past decade and a half, powerful evidence has accrued that modifications of LDL greatly increase its atherogenic potential, especially oxidative modification. 4 Goldstein et al5 were the first to show that modified LDL could be taken up by macrophages residing underneath the vascular endothelium, giving rise to foam cells and subsequently to the fatty streak, the earliest recognised gross lesion in atherogenesis. Chemical acetylation of LDL resulted in uptake at a rate 15 times greater than for unmodified (native) LDL. The reason for this was that such cells express few receptors for native LDL in vitro and in atherosclerotic lesions and these receptors are subject to downregulation.5 6 This "scavenger" receptor system also recognises other chemically modified forms of LDL, including acetoacetyl LDL7 and malondialdehyde conjugated LDL. 8 Aspirin (acetylsalicylic acid) is capable of acetylating human serum proteins, both in vitro and in vivo.9-'2 In addition, there is evidence to suggest that aspirin can itself generate free radicals.'3 14
Because of the known effects of chemical acetylation and free radical attack on LDL, both of which render it susceptible to catabolism by the macrophage scavenger receptor, we examined the effect of chemical modification of human LDL by aspirin, both in vivo and in vitro, on its potential for subsequent oxidative modification and hence its atherogenic potential.
Methods
Experiments were performed on normolipidaemic healthy volunteers from laboratory and medical staff before and after a two week treatment period with aspirin 300 mg daily. Informed consent was obtained.
All chemicals were obtained from BDH and Sigma Chemical Company and were of the highest grade and purity. PREPARATION Electrophoretic mobility of LDL There was no significant change in electrophoretic mobility of LDL following aspirin treatment. A highly significant increase in electrophoretic mobility following UVC irradiation (for four hours) was observed both before and after aspirin treatment. Importantly, the increase in relative electrophoretic mobility (migration distance of oxidised to native LDL) of LDL following UVC irradiation was significantly reduced following aspirin treatment (mean (SD) after aspirin, 2-17 (0 16) v before aspirin, 2-66 (0 24), P = 0-012 (fig 2) ) and this is in keeping with the observation that significantly less malondialdehyde was detected Most of the cholesterol entering the .ntrations macrophage is derived from serum lipoproirin treat-teins, especially LDL. The macrophage, how-*4 (12) v ever, expresses few receptors for native _DL pro-(unmodified) LDL, and hence uptake is slow.
In direct contrast, chemically modified LDL (acetylated, acetoacetylated, or malondialdehyde conjugated) is taken up rapidly by an by aspirin alternative receptor, the so called scavenger in, 0-028 receptor.578 nmol/mg
The apoprotein B epitopes which bind to no effect the scavenger receptor are formed almost , arachi-exclusively during the period when lipid There was hydroperoxides decompose to secondary ntent fol-oxidative products.25 In the case of LDL oxi-)) before dised in vitro, this corresponds to the decom-85 (3 12) position phase which follows oxidation,26 seen '4).
as a flattening off of the curve in fig 1. Oxidation of aspirin modified LDL by ultraviolet C irradiation was retarded to a UVC highly significant degree in these experiments. The malondialdehyde concentrations at the ondialde-start of the decomposition phase (four hours IC irradi-of UVC irradiation) were 30% less in the LDL ing LDL modified by aspirin in vivo (64-2 versus 89-6 malondi-nmol/mg LDL protein) and 65% less at the four and same time in the LDL modified by aspirin in ll signifi-vitro (33.4 versus 95-2 nmol/mg LDL proRed LDL tein). Thus the inherent capacity of LDL to I a fall in undergo oxidative modification to a degree following which renders it susceptible to uptake by the scavenger receptor is markedly reduced by aspirin, both in vivo and in vitro. Basal levels of malondialdehyde were also reduced by both in vitro and in vivo aspirin modification (24% and 48%, respectively), though this was only significant in the in vitro modified group. This suggests that aspirin is also able to reduce the inherent capacity of LDL to undergo oxidation.
As LDL becomes oxidised it undergoes a series of changes both in its physical and * t chemical properties. The malondialdehyde produced results in an increase in the net negative charge on the LDL molecule and renders it more mobile in an electrical field. The mechanism may involve both the binding of 8 h aldehyde to the free amino groups of lysine, 335 3 thus reducing the net positive charge, and free radical conversion of positively charged histidine and proline to the negatively charged aspartate and glutamate. 25 Jurgens et al26 showed a close linear relation between the relative electrophoretic mobility of modified LDL and its uptake into macrophages through the scavenger receptor. The scavenger receptor only recognises a certain pattern of negative charge on the apoprotein B molecule, with the density of charge at defined regions of the apoprotein B molecule being important. The relative electrophoretic mobility (REM) of the LDL following oxidation was significantly reduced by in vivo modification with aspirin (2 17 v 2 66), in keeping with the observation that significantly less malondialdehyde was produced (64-2 v 89-6 nmol/mg LDL protein).
The mechanism whereby aspirin affords LDL protection against oxidative modification is unclear, though there are several possible explanations.
Grootveld and Halliwell used aspirin to detect hydroxyl radical formation in vivo. 27 They showed that aspirin undergoes aromatic hydroxylation when exposed to hydroxyl radicals to form a specific set of hydroxylated products. With this in mind, it is possible that hydroxyl radicals formed when LDL undergoes oxidative modification, in this case following exposure to UVC irradiation, react with the aromatic nucleus of the salicylate molecule and are therefore neutralised.
Lysine residues in the LDL apoprotein B molecule are modified by malondialdehyde, rendering it susceptible to further oxidative modification and uptake by the scavenger system. 28 Aspirin too reacts by transferring its acetyl group to the lysine residues of human serum proteins, including LDL.'930 Malondialdehyde is also produced in human cataract as a byproduct of thromboxane synthesis. Aspirin inhibits the cross linking of human lens crystallin protein by malondialdehyde in vitro, by preventing access to the primary amino groups necessary for covalent cross linking and hence cataractogensis.31 A similar action may operate with respect to LDL oxidation. The fall in malondialdehyde concentration which occurs during the later stage of UVC oxidation of native LDL may be caused by the malondialdehyde complex being converted from the reversible Schiff base to an irreversible Amadori product, which is inaccessible to the TBA reaction. It is possible that aspirin prevents this process as described above. Thus-as was shown in these experiments-in aspirin modified LDL the concentration of malondialdehyde did not fall during the later stages of oxidation.
Aspirin could also be exerting an effect by inhibiting the prostaglandin generating system. Free radicals are generated through the prostaglandin synthase reaction and these are capable of initiating lipid peroxidation."
Aspirin has been shown to inhibit this sequence in experimental studies examining free radical production and lipid peroxidation, including rat heart." Against this would be the observation that aspirin exerted an inhibitory effect on lipid peroxidation not only in vivo but also in vitro. Similarly, an increase in the LDL content of the monounsaturated fatty acid, oleic acid, which almost doubled following aspirin treatment in vivo, would reduce the oxidisability of LDL,34 but again this would not account for the effect seen on LDL modified in vitro.
The in vivo and in vitro effects of aspirin on LDL oxidation seem to confer important benefit with regards to reducing its oxidisability, and hence its atherogenicity. However, modification of LDL by aspirin would at first sight be expected to render it more susceptible to macrophage uptake by virtue of its increased net negative charge and electrophoretic mobility. 26 Maziere et al did, however, show that such modified LDL is a poor candidate for uptake by the scavenger receptor, despite the electrochemical changes induced by aspirin derivatisation. 29 In conclusion, aspirin modifies LDL, both in vivo and in vitro, to a form which resists both endogenous and UVC induced oxidation, and this is likely to result in a significant reduction in the atherogenic potential of LDL. This study provides evidence of a hitherto unrecognised mechanism whereby aspirin offers protection against vascular disease and raises the question as to whether aspirin should play a routine part in the management of patients with dyslipidaemia. 
